glp-1 gastroparesis lawsuit in louisiana Drug-Induced and Product Liability Lawsuits involving popular GLP-1 medications

Emerging evidencestrengthened by ASCO GI 2026suggests that GLP-1 receptor agonists may define the next era by addressing the metabolic roots of colorectal carcinogenesis

Nausea ruins standard doses for many people

For the online panel component, invitations were sent to panel members by email followed by up to three reminder emails

Lancet 1(7897):1416

doi: 10.1136/bmj-2023-076197 26 HigginsJPThompsonSGDeeksJJAltmanDG

Citius is encouraged by the constructive engagement with the FDA, Leonard Mazur, the companys chairman and CEO, said in a statement on Friday, adding that Citius plans to complete the remediation activities by the end of 2023 and file a resubmission early in 2024